De Santis P, Sanna V, Perrone M, Guarini C, Santoro AN, Laface C, et al. Antibody–drug conjugates in HR+ breast cancer: Where are we now and where are we heading? J Clin Med. 2023;12(23):7325. https://doi.org/10.3390/jcm12237325.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Behranvand N, Nasri F, Zolfaghari Emameh R, Khani P, Hosseini A, Garssen J, et al. Chemotherapy: A double-edged sword in cancer treatment. Cancer Immunol Immunother. 2021;71(3):507–26. https://doi.org/10.1007/s00262-021-03013-3.

Article  PubMed  PubMed Central  Google Scholar 

Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783–91. https://doi.org/10.1056/nejmoa1209124.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Perez EA, Barrios C, Eiermann W, Toi M, Im YH, Conte P, et al. Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE. Cancer [Internet]. 2019;125(22):3974–84. Available from: https://pubmed.ncbi.nlm.nih.gov/31318460/. Accessed 16 Mar 2024.

Krop IE, Kim SB, Martin AG, LoRusso PM, Ferrero JM, Badovinac-Crnjevic T, et al. Trastuzumab emtansine versus treatment of physician’s choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol. 2017;18(6):743–54.

Article  CAS  PubMed  Google Scholar 

Von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617–28.

Article  Google Scholar 

Loibl S, Mano M, Untch M, et al. Phase III study of adjuvant ado-trastuzumab emtansine vs trastuzumab for residual invasive HER2-positive early breast cancer after neoadjuvant chemotherapy and HER2-targeted therapy. 2023 San Antonio Breast Cancer Symposium. Abstract GS03–12. Presented December 8, 2023.

Highlights of Prescribing Information [Internet]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed 16 Mar 2024.

Highlights of Prescribing Information [Internet]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125427lbl.pdf. Accessed 16 Mar 2024.

Doi T, Shitara K, Naito Y, Shimomura A, Fujiwara Y, Yonemori K, et al. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. Lancet Oncol. 2017;18(11):1512–22.

Article  CAS  PubMed  Google Scholar 

Tamura K, Tsurutani J, Takahashi S, Iwata H, Krop IE, Redfern C, et al. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. The Lancet Oncology [Internet]. 2019;20(6):816–26. Available from: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2819%2930097-X/fulltext. Accessed 16 Mar 2024.

Shitara K, Iwata H, Takahashi S, Tamura K, Park H, Modi S, et al. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study. Lancet Oncol. 2019;20(6):827–36.

Article  CAS  PubMed  Google Scholar 

Saura C, Modi S, Krop I, Park YH, Kim SB, Tamura K, et al. Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01). Ann Oncol. 2024;35(3):302–7.

Article  CAS  PubMed  Google Scholar 

Meric-Bernstam F, Makker V, Oaknin A, et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: Primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol. 2024;42(1):47–58. https://doi.org/10.1200/JCO.23.02005.

Article  CAS  PubMed  Google Scholar 

Center for Drug Evaluation and Research. (April 5th, 2024). FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for. U.S. Food and Drug Administration. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2. Accessed 16 Mar 2024.

André F, Hee Park Y, Kim SB, Takano T, Im SA, Borges G, et al. Trastuzumab deruxtecan versus treatment of physician’s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;401:1773–85.

Article  PubMed  Google Scholar 

Hurvitz SA, Modi S, Li W, Park YH, Chung W, Kim S-B, et al. 377O A pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with brain metastases (BMs) from DESTINY-Breast (DB) -01, -02, and -03. Ann Oncol. 2023;34:S335–6.

Article  Google Scholar 

Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab Deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387(1):9–20. https://doi.org/10.1056/nejmoa2203690.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Curigliano G. Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06). 2024. https://doi.org/10.1200/JCO.2024.42.17_suppl.LBA1000.

Highlights of Prescribing Information [Internet]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761115s035lbl.pdf. Accessed 16 Mar 2024.

Highlights of Prescribing Information [Internet]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761139s021lbl.pdf. Accessed 28 Mar 2024.

Tarantino P, Modi S, Tolaney SM, Cortés J, Hamilton EP, Kim SB, et al. Interstitial lung disease induced by anti-ERgBB2 antibody-drug conjugates. JAMA Oncol. 2021;7:1873–81.

Article  PubMed  Google Scholar 

Wekking D, Porcu M, Pellegrino B, Lai E, Mura G, Denaro N, et al. Multidisciplinary clinical guidelines in proactive monitoring, early diagnosis, and effective management of trastuzumab deruxtecan (T-DXd)-induced interstitial lung disease (ILD) in breast cancer patients. ESMO Open [Internet]. 2023;8(6):102043. Available from: https://www.sciencedirect.com/science/article/pii/S205970292301284X. Accessed 28 Mar 2024.

Chiu J, Chin Lee S, Ho JC, Hee Park Y, Chao T, Kim S, et al. Clinical guidance on the monitoring and management of Trastuzumab Deruxtecan (T-DXd)-related adverse events: insights from an Asia-Pacific multidisciplinary panel. Drug Safety. 2023;46(10):927–49.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Guerra E, Alberti S. The anti-Trop-2 antibody-drug conjugate sacituzumab govitecan—effectiveness, pitfalls and promises. Ann Transl Med. 2022;10(9):501–11.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384(16):1529–41.

Article  CAS  PubMed  Google Scholar 

Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, et al. Sacituzumab Govitecan-hziy in refractory metastatic triple-negative breast cancer. N Engl J Med. 2019;380(8):741–51.

Article  CAS  PubMed  Google Scholar 

Kalinsky K, Diamond JR, Vahdat LT, Tolaney SM, Juric D, O’Shaughnessy J, et al. Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial. Ann Oncol. 2020;31(12):1709–18.

Article  CAS  PubMed  Google Scholar 

Bardia A, Jhaveri K, Im SA, et al. Randomized phase 3 study of datopotamab deruxtecan vs chemotherapy for patients with previously treated inoperable or metastatic hormone receptor-positive, HER2-negative breast cancer: Results from TROPION-Breast01. Presented at: 2023 San Antonio Breast Cancer Symposium; December 5–9, 2023; San Antonio, TX. Abstract GS02–01.

Rugo HS, Bardia A, Marmé F, Cortes J, Schmid P, Loirat D, et al. Sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic Breast Cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical oncology [Internet]. 2022;40(29):3365–76. Available from: https://pubmed.ncbi.nlm.nih.gov/36027558/acc. Accessed 28 Mar 2024.

Rugo HS, Bardia A, Marmé F, Cortés J, Schmid P, Loirat D, et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. The Lancet [Internet]. 2023. Available from: https://www.sciencedirect.com/science/article/pii/S014067362301245X?via%3Dihub. Accessed 28 Mar 2024.

Manich S, O'Shaughnessy J, Aftimos E, Oesterholt M, et al. Primary outcome of the phase III SYD985.002/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician’s choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer. Ann Oncol. 2021;32. https://doi.org/10.1016/j.annonc.2021.08.2088.

Bartsch R, Berghoff AS, Furtner J, Marhold M, Bergen ES, Roider-Schur S, et al. Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial. Nature Medicine [Internet]. 2022;28(9):1840–7. Available from: https://pubmed.ncbi.nlm.nih.gov/35941372. Accessed 28 Mar 2024.

Huppert LA, Mahtani RL, Fisch SC. Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC): Updated data and subgroup analyses by age, sites of disease, and use of intervening therapies. J Clin Oncol. ASCO 2024;42(16). https://doi.org/10.1200/JCO.2024.42.16_suppl.1083.

Abelman RO, et al. Presented at San Antonio Breast Cancer Symposium 2023. Abstract PS08–03.

Criscitiello C. Tumor-associated antigens in breast cancer. Breast Care [Internet]. 2012;7(4):262–6. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3515784/. Accessed 28 Mar 2024.

Hunter FW, Barker HR, Lipert B, Rothé F, Gebhart G, Piccart-Gebhart MJ, et al. Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer. British Journal of Cancer [Internet]. 2020;122(5):603–12. Available from: https://www.nature.com/articles/s41416-019-0635-y. Accessed 28 Mar 2024.

Barok M, Joensuu H, Isola J. Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res. 2014;16(2). https://doi.org/10.1186/bcr3621.

Filho OM, Viale G, Stein S, Trippa L, Yardley DA, Mayer IA, et al. Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer: Phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab. Cancer Discov. 2021;11(10):2474–87.

Article  CAS  PubMed  PubMed Central  Google Scholar 

García-Alonso S, Ocaña A, Pandiella A. Resistance to antibody–drug conjugates. Can Res. 2018;78(9):2159–65.

Article  Google Scholar 

Sung M, Tan X, Lu B, Golas J, Hosselet C, Wang F, et al. Caveolae-mediated endocytosis as a novel mechanism of resistance to trastuzumab emtansine (T-DM1). Mol Cancer Ther. 2018;17(1):243–53.

Article  CAS  PubMed  Google Scholar 

Network CGA. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70. https://doi.org/10.1038/nature11412.

Article  CAS  Google Scholar 

Kumar S, Sherman MY. Resistance to TOP-1 inhibitors: Good old drugs still can surprise Us. Int J Mol Sci. 2023;24(8):7233.

Article  CAS  PubMed